Replimune(US:REPL) Prnewswireยท2025-07-29 14:22Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to allegations of violations of federal securities laws related to misleading statements about the IGNYTE trial and its FDA approval process [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Replimune and its executives made false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [4]. Group 2: Impact of FDA Response - On July 22, 2025, Replimune received a Complete Response Letter (CRL) from the FDA, indicating that the application for RP1 was not approved in its current form due to inadequacies in the IGNYTE trial [5]. - Following the announcement of the CRL, Replimune's stock price fell over 73% during intraday trading on the same day [5]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Replimune's conduct [7].